PO.CL01.23 · 临床研究
来自原发性乳腺癌患者的历史冷冻保存骨髓样本中播散性肿瘤细胞的遗传学表征
Genetic characterization of disseminated tumor cells of historical cryo-preserved bone marrow samples from primary breast cancer patients
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:转移性复发是激素受体阳性、HER2阴性原发性乳腺癌(BC)患者死亡的主要原因。虽然一些患者在超过10年后出现晚期复发,而另一些患者在3-7年内复发,但这种差异背后的生物学机制仍知之甚少。骨髓(BM)中的播散性肿瘤细胞(DTCs)被假设为驱动转移进展的一个临床隐匿性储库。在本研究中,我们表征了DTCs的基因组改变,以确定它们与匹配的原发肿瘤(PTs)之间的克隆关系,并区分导致早期与晚期复发的基因组特征。
方法:我们的研究基于一个冷冻保存的BM样本队列,这些样本在诊断时采集自2006年至2012年间接受治疗、随访超过12年的600名BC患者。从该队列中,我们选取了先前使用标准化免疫细胞化学检测诊断为DTC阳性的BM样本。在本研究中,我们建立了一个工作流程,使用CellSearch®系统从冷冻保存的BM中检测和分离DTCs。解冻后,每个样本处理多达2000万个单个核细胞,使用CellSearch®检测EpCAM⁺/DAPI⁺/CK⁺/CD45⁻的DTCs(CS-DTCs)。随后分离单个CS-DTCs,并使用接头-连接子PCR扩增其全基因组。进行低深度下一代测序(NGS)以评估拷贝数改变(CNAs)。
结果:到目前为止,我们在35个先前诊断为DTC阳性的BM样本中的31个中检测并分离出了CS-DTCs。在我们初步的CNA分析中,75%的CS-DTCs显示出BC特征性的异常拷贝数谱,而匹配的白细胞则显示正常的基因组谱。在迄今分析的一名患者中,我们分离出16个CS-DTCs,它们显示出共有的克隆性CNA模式,然而个别CS-DTCs也携带私有CNAs。目前正在处理更多的BM样本及其对应的PTs,以便直接比较DTCs与其匹配的原发肿瘤。
结论:我们的初步结果表明,这种基于CellSearch®的工作流程能够可靠地检测、分离和表征来自长期冷冻保存BM样本的单个DTCs。该方法为探索DTCs与PTs之间的克隆关系提供了一个稳健的平台。总体目标是揭示BC中微小残留病和复发背后的机制。
查看英文原文 English abstract
Background: Metastatic relapse is the leading cause of death in patients with hormone receptor-positive, HER2-negative primary breast cancer (BC). While some patients experience late relapse after more than 10 years, others relapse within 3-7 years, yet the biological mechanisms underlying this variability remain poorly understood. Disseminated tumor cells (DTCs) in the bone marrow (BM) are hypothesized to represent a clinically occult reservoir driving metastatic progression. In this study we characterized genomic alterations of DTCs to define their clonal relationship to matched primary tumors (PTs) and distinguish genomic features contributing to early versus late relapse.
Methods: Our study is based on a cohort of cryopreserved BM samples collected at diagnosis from 600 BC patients treated between 2006 and 2012 with more than 12 years of follow-up. From this cohort, we selected BM samples previously diagnosed as DTC-positive using a standardized immunocytochemistry assay. For this study, we established a workflow to detect and isolate DTCs from cryopreserved BM using the CellSearch® system. After thawing, up to 20 Mio mononuclear cells per sample were processed with CellSearch® for the detection of EpCAM⁺/DAPI⁺/CK⁺/CD45⁻ DTCs (CS-DTCs). Individual CS-DTCs were subsequently isolated, and their whole genomes were amplified using adapter-linker PCR. Low-pass next-generation sequencing (NGS) was performed to assess copy-number alterations (CNAs).
Results: Thus far, we detected and isolated CS-DTCs in 31/35 BM samples previously diagnosed as DTC-positive. In our initial CNA analysis, 75% of CS-DTCs displayed aberrant copy-number profiles characteristic of BC, whereas matched white blood cells showed normal genomic profiles. In one patient analyzed to date, we isolated 16 CS-DTCs demonstrating a shared clonal CNA pattern, however, individual CS-DTCs also harbored private CNAs. Additional BM samples and the corresponding PTs are currently being processed to enable direct comparison of DTCs with their matched primaries.
Conclusions: Our preliminary results demonstrate that this CellSearch®-based workflow enables reliable detection, isolation, and genomic characterization of single DTCs from long-term cryopreserved BM samples. This approach provides a robust platform for exploring clonal relationships between DTCs and PTs. The overall aim is to uncover mechanisms underlying minimal residual disease and relapse in BC.
利益披露 Disclosure
A. Rohloff, None..
R. P. Lousa Das Neves, None..
C. Driemel, None..
D. Doerr, None.
O. Hoffmann,
Roche Other, Honoraria for advisory boards and lectures.
Astra Zeneca Other, Honoraria for advisory boards and lectures.
Stemline Menarini Other, Honoraria for advisory boards and lectures.
Amgen Other, Honoraria for advisory boards and lectures.
Pfizer Other, Honoraria for advisory boards and lectures.
Elsai Other, Honoraria for advisory boards and lectures.
Gilead Other, Honoraria for advisory boards and lectures.
Hexal Other, Honoraria for advisory boards and lectures.
MSD Other, Honoraria for advisory boards and lectures.
Novartis Other, Honoraria for advisory boards and lectures.
Seagen Other, Honoraria for advisory boards and lectures.
Daiichi Sankyo Other, Honoraria for advisory boards and lectures.
Alpinion Other, Honoraria for advisory boards and lectures.
R. Kimmig,
Avatera Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
CMR Surgical Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
Active Surgical Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
Cava Robotics Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
Intuitive Surgical Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
Medtronic Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
Distalmotion Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
Novocure Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
Medicaroid Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
GSK Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
MSD Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
Astra-Zeneca Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
Tesaro. Other, honoraria for Proctoring, Advisory Board, Presentations, Travel support.
N. H. Stoecklein,
Menarini Silicon ).
TZU Cancer Therapeutics Other, Advisory Board Fees.
S. Kasimir-Bauer,
Qiagen Other, Consultant.
GILEAD ).